David Llewellyn (L) and Joe Illingworth, DJS Antibodies co-founders
October 20, 2022 10:45 AM EDT
Deals

Ab­b­Vie re­cruits a GPCR team in Ox­ford, buy­ing out a fledg­ling biotech for $255M+

John Carroll

Editor & Founder

Less than 2 years af­ter some Ox­ford grads pieced to­geth­er a lit­tle £6 mil­lion seed fund to launch their dis­cov­ery out­fit, the an­ti­body de­vel­op­er has …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

David Ep­stein gets $140M for Ot­ti­mo's bi­func­tion­al take on hot PD-1xVEGF field

A service from the Financial Times